Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southern Cancer Center
Mobile, Alabama, United States
- Scripps Cancer Center
La Jolla, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Florida Cancer Specialists South
Fort Myers, Florida, United States
- Woodlands Medical Specialists
Pensacola, Florida, United States
- Florida Cancer Specialists North
St. Petersburg, Florida, United States
- Florida Cancer Specialist and Research Institute
Tallahassee, Florida, United States
- H. Lee Moffitt Cancer Center
Tampa, Florida, United States
- Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
- Indiana University Simon Cancer Ctr
Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Baltimore, Maryland, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Michigan State University
Lansing, Michigan, United States
- Nebraska Methodist
Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- Weill Cornell Medical Center
New York, New York, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Tennessee Oncology - Chattanooga
Chattanooga, Tennessee, United States
- Sarah Cannon Cancer Center, Tennessee Oncology
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Cancer Care Centers of South Texas
San Antonio, Texas, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2013
- Primary completion
- 30 Nov 2015
- Completion
- 30 Nov 2016
- Last update posted
- 13 Sept 2018
- Registered enrollment
- 102
- Registry id
- NCT01873703
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.